RedHill Biopharma Ltd. (RDHL) Monday said Opaganib, the company's antiviral drug candidate for the treatment of Covid-19, showed strong inhibition against South African and Brazilian variants in preclinical study.
Partnered with the University of Louisville Center for Predictive Medicine, opaganib was studied in a 3D tissue model of human bronchial epithelial cells to evaluate the in vitro efficacy of opaganib in inhibiting the Beta, South African and Gamma, Brazilian SARS-CoV-2 variants.
Opaganib exerts its antiviral effect by selectively inhibiting sphingosine kinase-2 (SK2), a key enzyme produced in human cells that can be recruited by the virus to support its replication.
RedHill Biopharma said opaganib's Phase 2/3 study in hospitalized patients with Covid-19 is fully enrolled and is expected to be completed in the coming weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.